M

MoonLake Immunotherapeutics
NASDAQ:MLTX

Watchlist Manager
MoonLake Immunotherapeutics
NASDAQ:MLTX
Watchlist
Price: 51.425 USD -0.84%
Market Cap: 3.3B USD
Have any thoughts about
MoonLake Immunotherapeutics?
Write Note

Intrinsic Value

MLTX's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

The intrinsic value of one MLTX stock under the Base Case scenario is 7.717 USD. Compared to the current market price of 51.425 USD, MoonLake Immunotherapeutics is Overvalued by 85%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

MLTX Intrinsic Value
7.717 USD
Overvaluation 85%
Intrinsic Value
Price
M
Worst Case
Base Case
Best Case

Valuation Backtest
MoonLake Immunotherapeutics

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for MLTX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about MLTX?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
MoonLake Immunotherapeutics

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about MoonLake Immunotherapeutics

Provide an overview of the primary business activities
of MoonLake Immunotherapeutics.

What unique competitive advantages
does MoonLake Immunotherapeutics hold over its rivals?

What risks and challenges
does MoonLake Immunotherapeutics face in the near future?

Has there been any significant insider trading activity
in MoonLake Immunotherapeutics recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for MoonLake Immunotherapeutics.

Provide P/S
for MoonLake Immunotherapeutics.

Provide P/E
for MoonLake Immunotherapeutics.

Provide P/OCF
for MoonLake Immunotherapeutics.

Provide P/FCFE
for MoonLake Immunotherapeutics.

Provide P/B
for MoonLake Immunotherapeutics.

Provide EV/S
for MoonLake Immunotherapeutics.

Provide EV/GP
for MoonLake Immunotherapeutics.

Provide EV/EBITDA
for MoonLake Immunotherapeutics.

Provide EV/EBIT
for MoonLake Immunotherapeutics.

Provide EV/OCF
for MoonLake Immunotherapeutics.

Provide EV/FCFF
for MoonLake Immunotherapeutics.

Provide EV/IC
for MoonLake Immunotherapeutics.

Show me price targets
for MoonLake Immunotherapeutics made by professional analysts.

What are the Revenue projections
for MoonLake Immunotherapeutics?

How accurate were the past Revenue estimates
for MoonLake Immunotherapeutics?

What are the Net Income projections
for MoonLake Immunotherapeutics?

How accurate were the past Net Income estimates
for MoonLake Immunotherapeutics?

What are the EPS projections
for MoonLake Immunotherapeutics?

How accurate were the past EPS estimates
for MoonLake Immunotherapeutics?

What are the EBIT projections
for MoonLake Immunotherapeutics?

How accurate were the past EBIT estimates
for MoonLake Immunotherapeutics?

Compare the revenue forecasts
for MoonLake Immunotherapeutics with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of MoonLake Immunotherapeutics and its key competitors using the latest financial data.

Compare historical revenue growth rates
of MoonLake Immunotherapeutics against its competitors.

Analyze the profit margins
(gross, operating, and net) of MoonLake Immunotherapeutics compared to its peers.

Compare the P/E ratios
of MoonLake Immunotherapeutics against its peers.

Discuss the investment returns and shareholder value creation
comparing MoonLake Immunotherapeutics with its peers.

Analyze the financial leverage
of MoonLake Immunotherapeutics compared to its main competitors.

Show all profitability ratios
for MoonLake Immunotherapeutics.

Provide ROE
for MoonLake Immunotherapeutics.

Provide ROA
for MoonLake Immunotherapeutics.

Provide ROIC
for MoonLake Immunotherapeutics.

Provide ROCE
for MoonLake Immunotherapeutics.

Provide Gross Margin
for MoonLake Immunotherapeutics.

Provide Operating Margin
for MoonLake Immunotherapeutics.

Provide Net Margin
for MoonLake Immunotherapeutics.

Provide FCF Margin
for MoonLake Immunotherapeutics.

Show all solvency ratios
for MoonLake Immunotherapeutics.

Provide D/E Ratio
for MoonLake Immunotherapeutics.

Provide D/A Ratio
for MoonLake Immunotherapeutics.

Provide Interest Coverage Ratio
for MoonLake Immunotherapeutics.

Provide Altman Z-Score Ratio
for MoonLake Immunotherapeutics.

Provide Quick Ratio
for MoonLake Immunotherapeutics.

Provide Current Ratio
for MoonLake Immunotherapeutics.

Provide Cash Ratio
for MoonLake Immunotherapeutics.

What is the historical Revenue growth
over the last 5 years for MoonLake Immunotherapeutics?

What is the historical Net Income growth
over the last 5 years for MoonLake Immunotherapeutics?

What is the current Free Cash Flow
of MoonLake Immunotherapeutics?

Discuss the annual earnings per share (EPS)
trend over the past five years for MoonLake Immunotherapeutics.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
MoonLake Immunotherapeutics

Current Assets 512.3m
Cash & Short-Term Investments 493.9m
Receivables 17.6m
Other Current Assets 747.2k
Non-Current Assets 5.9m
PP&E 3.8m
Other Non-Current Assets 2.1m
Current Liabilities 20.1m
Accounts Payable 10.3m
Accrued Liabilities 9.4m
Other Current Liabilities 449k
Non-Current Liabilities 9.9m
Other Non-Current Liabilities 9.9m
Efficiency

Earnings Waterfall
MoonLake Immunotherapeutics

Revenue
0 USD
Operating Expenses
-108.5m USD
Operating Income
-108.5m USD
Other Expenses
27.8m USD
Net Income
-80.8m USD

Free Cash Flow Analysis
MoonLake Immunotherapeutics

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

MLTX Profitability Score
Profitability Due Diligence

MoonLake Immunotherapeutics's profitability score is 42/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROIC
Negative Free Cash Flow
Negative Operating Income
Negative Net Income
42/100
Profitability
Score

MoonLake Immunotherapeutics's profitability score is 42/100. The higher the profitability score, the more profitable the company is.

MLTX Solvency Score
Solvency Due Diligence

MoonLake Immunotherapeutics's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

MoonLake Immunotherapeutics's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

MLTX Price Targets Summary
MoonLake Immunotherapeutics

Wall Street analysts forecast MLTX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MLTX is 75.402 USD with a low forecast of 55.55 USD and a high forecast of 109.2 USD.

Lowest
Price Target
55.55 USD
8% Upside
Average
Price Target
75.402 USD
47% Upside
Highest
Price Target
109.2 USD
112% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for MLTX?

Click here to dive deeper.

Dividends

MoonLake Immunotherapeutics
does not pay dividends
Shareholder Yield

Current shareholder yield for MLTX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

MLTX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

MoonLake Immunotherapeutics

Country

Switzerland

Industry

N/A

Market Cap

3.2B USD

Dividend Yield

0%

Description

MoonLake Immunotherapeutics is a CH-based company operating in industry. The company is headquartered in Zug, Zug. The company went IPO on 2020-10-20. MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The firm develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.

Contact

ZUG
Zug
Dorfstrasse 29
+41415108022

IPO

2020-10-20

Employees

-

Officers

Co-Founder, CEO & Director
Dr. Jorge Santos da Silva
Co-Founder & Chief Scientific Officer
Dr. Kristian Reich
Chief Financial Officer
Mr. Matthias Bodenstedt
Chief Operations Officer
Mr. Oliver Daltrop Ph.D.
Director Investor Relations & Business Development
Ms. Carla Bretes
General Counsel
Mr. Nicolas Mosimann
Show More
Sr. Director Legal & Compliance
Joana Cortez
Vice President of Marketing, Market Access & Pricing
Tino Anthamatten
Director of HR, People & Culture
Luciana Marques
Chief Clinical Development Officer
Ms. Nuala Brennan
Show Less

See Also

Discover More
What is the Intrinsic Value of one MLTX stock?

The intrinsic value of one MLTX stock under the Base Case scenario is 7.717 USD.

Is MLTX stock undervalued or overvalued?

Compared to the current market price of 51.425 USD, MoonLake Immunotherapeutics is Overvalued by 85%.

Back to Top